

Dr. Reddy's launches antidepressants in the US market

06 September 2017 | News

Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, is a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Tablets.



Dr. Reddy's Laboratories Ltd. has launched Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Tablets, approved by the U.S. Food & Drug Administration (USFDA).

Bupropion Hydrochloride Extended-Release Tablets, an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines.

The Wellbutrin XL brand and generic had U.S. sales of approximately \$754 million MAT for the most recent twelve months ending in July 2017 according to IMS Health.

Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, are each available in bottle count sizes of 30, 90 and 500.

Wellbutrin XL is a trademark of GlaxoSmithKline LLC.